Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Neuro-oncologists have spoken - the role of bevacizumab in the inpatient setting. A clinical and economic conundrum.

Sharma A, Low J, Mrugala MM.

Neurooncol Pract. 2019 Jan;6(1):30-36. doi: 10.1093/nop/npy011. Epub 2018 Apr 19.

PMID:
31385984
2.

ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach.

Johnston SK, Whitmire P, Massey SC, Kumthekar P, Porter AB, Raghunand N, Gonzalez-Cuyar LF, Mrugala MM, Hawkins-Daarud A, Jackson PR, Hu LS, Sarkaria JN, Wang L, Gatenby RA, Egan KM, Canoll P, Swanson KR; ENDURES consortium.

Am J Clin Oncol. 2019 Aug;42(8):655-661. doi: 10.1097/COC.0000000000000564.

PMID:
31343422
3.

Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer.

Mrugala MM, Kim B, Sharma A, Johnson N, Graham C, Kurland BF, Gralow J.

Clin Breast Cancer. 2019 Oct;19(5):311-316. doi: 10.1016/j.clbc.2019.04.004. Epub 2019 Apr 18.

PMID:
31175053
4.

Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, Van den Bent M, Vogelbaum MA.

Neuro Oncol. 2019 Mar 18;21(4):424-427. doi: 10.1093/neuonc/noz034.

PMID:
30883663
5.

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NTN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, van den Bent M, Vogelbaum MA.

J Clin Oncol. 2019 May 1;37(13):1130-1135. doi: 10.1200/JCO.18.02085. Epub 2019 Mar 18.

PMID:
30883246
6.

Accurate Patient-Specific Machine Learning Models of Glioblastoma Invasion Using Transfer Learning.

Hu LS, Yoon H, Eschbacher JM, Baxter LC, Dueck AC, Nespodzany A, Smith KA, Nakaji P, Xu Y, Wang L, Karis JP, Hawkins-Daarud AJ, Singleton KW, Jackson PR, Anderies BJ, Bendok BR, Zimmerman RS, Quarles C, Porter-Umphrey AB, Mrugala MM, Sharma A, Hoxworth JM, Sattur MG, Sanai N, Koulemberis PE, Krishna C, Mitchell JR, Wu T, Tran NL, Swanson KR, Li J.

AJNR Am J Neuroradiol. 2019 Mar;40(3):418-425. doi: 10.3174/ajnr.A5981. Epub 2019 Feb 28.

7.

Next-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Leptomeningeal Carcinomatosis: Review of 2 Cases.

Grimsrud KW, Mrugala MM.

Neurologist. 2019 Mar;24(2):59-61. doi: 10.1097/NRL.0000000000000220.

PMID:
30817492
8.

The Use of Recombinant Poliovirus for the Treatment of Recurrent Glioblastoma Multiforme.

Abi-Aad KR, Turcotte EL, Welz ME, Krishna C, Mrugala MM, Porter AB, Vora SA, Bendok BR.

World Neurosurg. 2019 Jan 22. pii: S1878-8750(19)30147-0. doi: 10.1016/j.wneu.2019.01.050. [Epub ahead of print] No abstract available.

PMID:
30682513
9.

Disseminated High-grade Glioma in a Long-term Survivor of Medulloblastoma: Implications and Management of Radiation-induced Malignancies.

Porter AB, Sio TT, Nelson KD, Raghunathan A, Bendok BR, Mrugala MM.

Neurologist. 2018 Nov;23(6):191-193. doi: 10.1097/NRL.0000000000000199.

PMID:
30379742
10.

A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.

Wenger C, Miranda PC, Salvador R, Thielscher A, Bomzon Z, Giladi M, Mrugala MM, Korshoej AR.

IEEE Rev Biomed Eng. 2018;11:195-207. doi: 10.1109/RBME.2017.2765282. Epub 2018 Feb 13. Review.

PMID:
29993870
11.

Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice.

Lukas RV, Mrugala MM.

Neurooncol Pract. 2017 Dec;4(4):209-219. doi: 10.1093/nop/npw016. Epub 2016 Aug 26. Review.

12.

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A.

J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345. doi: 10.6004/jnccn.2017.0166.

PMID:
29118226
13.

Tumor Treating Fields in Neuro-Oncological Practice.

Mrugala MM, Ruzevick J, Zlomanczuk P, Lukas RV.

Curr Oncol Rep. 2017 Aug;19(8):53. doi: 10.1007/s11912-017-0611-8. Review.

PMID:
28664468
14.

Management of Leptomeningeal Disease From Solid Tumors.

Lukas RV, Buerki R, Mrugala MM.

Oncology (Williston Park). 2016 Aug;30(8):724-30. Review. No abstract available.

15.

Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience.

Ly KI, Crew LL, Graham CA, Mrugala MM.

Oncol Lett. 2016 May;11(5):3471-3476. Epub 2016 Mar 30.

16.

Reply to comment on: 'Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach'.

Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC, Swanson KR.

Phys Med Biol. 2016 Apr 7;61(7):2968-9. doi: 10.1088/0031-9155/61/7/2968. Epub 2016 Mar 17. No abstract available.

PMID:
26988701
17.

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.

Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H.

Am J Clin Oncol. 2018 Feb;41(2):159-162. doi: 10.1097/COC.0000000000000247.

PMID:
26658237
18.

Addendum to 'A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET'.

Rockne RC, Trister AD, Jacobs J, Hawkins-Daarud AJ, Neal ML, Hendrickson K, Mrugala MM, Rockhill JK, Kinahan P, Krohn KA, Swanson KR.

J R Soc Interface. 2015 Nov 6;12(112). pii: 20150927. doi: 10.1098/rsif.2015.0927. No abstract available.

PMID:
26577597
Free PMC Article
19.

Central Nervous System Cancers, Version 1.2015.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM.

J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202.

PMID:
26483059
20.

Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.

Ly KI, Hamilton SR, Rostomily RC, Rockhill JK, Mrugala MM.

J Neuroophthalmol. 2015 Dec;35(4):382-6. doi: 10.1097/WNO.0000000000000253.

PMID:
26049681
21.

A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.

Malek N, Mrugala M, Makuch W, Kolosowska N, Przewlocka B, Binkowski M, Czaja M, Morera E, Di Marzo V, Starowicz K.

Pain. 2015 May;156(5):890-903. doi: 10.1097/j.pain.0000000000000132. Erratum in: Pain. 2015 Jul;156(7):1370.

PMID:
25719612
22.

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH.

Neuro Oncol. 2015 Jun;17(6):854-61. doi: 10.1093/neuonc/nou348. Epub 2015 Jan 13.

23.

A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET.

Rockne RC, Trister AD, Jacobs J, Hawkins-Daarud AJ, Neal ML, Hendrickson K, Mrugala MM, Rockhill JK, Kinahan P, Krohn KA, Swanson KR.

J R Soc Interface. 2015 Feb 6;12(103). pii: 20141174. doi: 10.1098/rsif.2014.1174. Erratum in: J R Soc Interface. 2015 Nov 6;12(112). pii: 20150927. doi: 10.1098/rsif.2015.0927.

24.

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M.

J Natl Compr Canc Netw. 2014 Nov;12(11):1517-23.

25.

Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas.

Baldock AL, Ahn S, Rockne R, Johnston S, Neal M, Corwin D, Clark-Swanson K, Sterin G, Trister AD, Malone H, Ebiana V, Sonabend AM, Mrugala M, Rockhill JK, Silbergeld DL, Lai A, Cloughesy T, McKhann GM 2nd, Bruce JN, Rostomily RC, Canoll P, Swanson KR.

PLoS One. 2014 Oct 28;9(10):e99057. doi: 10.1371/journal.pone.0099057. eCollection 2014.

26.

Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N.

Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e33-43.

27.

Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.

Adair JE, Johnston SK, Mrugala MM, Beard BC, Guyman LA, Baldock AL, Bridge CA, Hawkins-Daarud A, Gori JL, Born DE, Gonzalez-Cuyar LF, Silbergeld DL, Rockne RC, Storer BE, Rockhill JK, Swanson KR, Kiem HP.

J Clin Invest. 2014 Sep;124(9):4082-92. doi: 10.1172/JCI76739. Epub 2014 Aug 8.

28.

Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.

Baldock AL, Yagle K, Born DE, Ahn S, Trister AD, Neal M, Johnston SK, Bridge CA, Basanta D, Scott J, Malone H, Sonabend AM, Canoll P, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR.

Neuro Oncol. 2014 Jun;16(6):779-86. doi: 10.1093/neuonc/nou027.

29.

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.

Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, Rice L, McCarthy K, Johnston SK, Mrugala MM, Chamberlain M.

J Neurooncol. 2014 Mar;117(1):93-101. doi: 10.1007/s11060-014-1358-9. Epub 2014 Jan 22.

PMID:
24449400
30.

Toward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma.

Corwin D, Holdsworth C, Rockne RC, Trister AD, Mrugala MM, Rockhill JK, Stewart RD, Phillips M, Swanson KR.

PLoS One. 2013 Nov 12;8(11):e79115. doi: 10.1371/journal.pone.0079115. eCollection 2013.

31.

Central nervous system cancers.

Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1114-51.

32.
33.

From patient-specific mathematical neuro-oncology to precision medicine.

Baldock AL, Rockne RC, Boone AD, Neal ML, Hawkins-Daarud A, Corwin DM, Bridge CA, Guyman LA, Trister AD, Mrugala MM, Rockhill JK, Swanson KR.

Front Oncol. 2013 Apr 2;3:62. doi: 10.3389/fonc.2013.00062. eCollection 2013.

34.

Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article.

Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S.

J Neurosurg. 2013 Jun;118(6):1183-7. doi: 10.3171/2013.1.JNS12397. Epub 2013 Mar 1.

PMID:
23451905
35.

Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.

Neal ML, Trister AD, Ahn S, Baldock A, Bridge CA, Guyman L, Lange J, Sodt R, Cloke T, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR.

Cancer Res. 2013 May 15;73(10):2976-86. doi: 10.1158/0008-5472.CAN-12-3588. Epub 2013 Feb 11.

36.

Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric.

Neal ML, Trister AD, Cloke T, Sodt R, Ahn S, Baldock AL, Bridge CA, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR.

PLoS One. 2013;8(1):e51951. doi: 10.1371/journal.pone.0051951. Epub 2013 Jan 23.

37.

Carboplatin and bevacizumab for recurrent malignant glioma.

Mrugala MM, Crew LK, Fink JR, Spence AM.

Oncol Lett. 2012 Nov;4(5):1082-1086. Epub 2012 Aug 1.

38.

Chemoprotection in glioblastoma therapy: reality or a dream?

Mrugala MM, Adair J, Kiem HP.

CNS Oncol. 2012 Sep;1(1):11-4. doi: 10.2217/cns.12.11. No abstract available.

39.

Extended survival of glioblastoma patients after chemoprotective HSC gene therapy.

Adair JE, Beard BC, Trobridge GD, Neff T, Rockhill JK, Silbergeld DL, Mrugala MM, Kiem HP.

Sci Transl Med. 2012 May 9;4(133):133ra57. doi: 10.1126/scitranslmed.3003425.

40.

Outside the box--novel therapeutic strategies for glioblastoma.

Mrugala MM, Adair JE, Kiem HP.

Cancer J. 2012 Jan-Feb;18(1):51-8. doi: 10.1097/PPO.0b013e318243f785. Review.

PMID:
22290258
41.

Central nervous system cancers.

Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Vrionis FD, Wen PY; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Apr;9(4):352-400. No abstract available.

PMID:
21464144
42.

Temozolomide: Expanding its role in brain cancer.

Mrugala MM, Adair J, Kiem HP.

Drugs Today (Barc). 2010 Nov;46(11):833-46. doi: 10.1358/dot.2010.46.11.1549024. Review.

PMID:
21225022
43.

Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach.

Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC Jr, Swanson KR.

Phys Med Biol. 2010 Jun 21;55(12):3271-85. doi: 10.1088/0031-9155/55/12/001. Epub 2010 May 18.

44.

Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model.

Wang CH, Rockhill JK, Mrugala M, Peacock DL, Lai A, Jusenius K, Wardlaw JM, Cloughesy T, Spence AM, Rockne R, Alvord EC Jr, Swanson KR.

Cancer Res. 2009 Dec 1;69(23):9133-40. doi: 10.1158/0008-5472.CAN-08-3863. Epub 2009 Nov 24.

45.

Genetic determinants of hearing loss associated with vestibular schwannomas.

Stankovic KM, Mrugala MM, Martuza RL, Silver M, Betensky RA, Nadol JB Jr, Stemmer-Rachamimov AO.

Otol Neurotol. 2009 Aug;30(5):661-7. doi: 10.1097/MAO.0b013e3181a66ece.

PMID:
19546833
46.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Mrugala MM.

Neurology. 2009 Feb 24;72(8):773; author reply 773-4. No abstract available.

PMID:
19248218
47.

Insights into the biology of primary central nervous system lymphoma.

Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT.

Curr Oncol Rep. 2009 Jan;11(1):73-80. Review.

48.

High-dose methotrexate for elderly patients with primary CNS lymphoma.

Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, Batchelor TT.

Neuro Oncol. 2009 Apr;11(2):211-5. doi: 10.1215/15228517-2008-067. Epub 2008 Aug 29.

49.

Mechanisms of disease: temozolomide and glioblastoma--look to the future.

Mrugala MM, Chamberlain MC.

Nat Clin Pract Oncol. 2008 Aug;5(8):476-86. doi: 10.1038/ncponc1155. Epub 2008 Jun 10. Review.

PMID:
18542116
50.

Central nervous system cancers.

Brem SS, Bierman PJ, Black P, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Glass J, Grossman SA, Heimberger AB, Junck L, Linette GP, Loeffler JJ, Maor MH, Moots P, Mrugala M, Nabors LB, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Shrieve DC, Sills AK Jr.

J Natl Compr Canc Netw. 2008 May;6(5):456-504. No abstract available.

PMID:
18492461

Supplemental Content

Loading ...
Support Center